Similar companies
Income Statement ()
| Q1 '26 | QoQ | |
|---|---|---|
| Revenue | 731M | 65% |
| Gross Profit | 611M | 1282.5% |
| Cost of Revenue | 119M | 70.1% |
| Operating expense | 253M | 44.5% |
| Net Income | 331M | 217% |
| EBITDA | 372M | 247.6% |
Balance Sheet ()
| Q1 '26 | QoQ | |
|---|---|---|
| Total Assets | 3.18B | 5.1% |
| Total Liabilities | 1.67B | 24.2% |
| Total Equity | 1.51B | 32% |
| Shares Outstanding | 122M | 16.3% |
Cash Flow ()
| Q1 '26 | QoQ | |
|---|---|---|
| Cash from operations | -203M | 254.5% |
| Cash from investing | -134M | 239.7% |
| Cash from financing | 240,000 | 100.6% |
EPS
Financial Highlights for Sarepta Therapeutics in Q1 '26
Sarepta Therapeutics reported a revenue of 731M, which is a 65% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 611M, marking a 1282.5% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 119M, a -70.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 253M, showing a -44.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 331M, showing a 217% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 372M, showing a 247.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Sarepta Therapeutics with growth in revenue, gross profit, and net income.
